HTBX Heat Biologics Inc

Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, CEO of Heat is scheduled to present at the following investor conferences:

BIO Investor Forum

Date: Tuesday, October 18, 2016Time:  3:30 PM Eastern TimeLocation: Westin St. Francis Hotel in San Francisco, CAMain Therapeutic Focus: ImmunologyWebcast: http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.

The Dawson James Growth Stock Conference

Date: Thursday, October 20, 2016Time: 10:00 AM Eastern TimeLocation: Wyndham Grand Hotel in Jupiter, FLWebcast: http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.

Additionally, Chief Scientific Officer, Taylor Schreiber, M.D., Ph.D., will participate in a panel discussion on “The Sizzling Science and Business of Immuno-Oncology” at the North Carolina Biotechnology Center, on October 25th, from 4-7 PM. For more information on the panel please go to: http://www.ncbiotech.org/event/life-sciences-forum/191426.

About Heat Biologics, Inc. Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer.  Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates.  These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response.  Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC).  For more information, please visit www.heatbio.com.

CONTACT:
For Investor Inquiries: 
David Waldman
919-240-7133
Investorrelations@heatbio.com

For Media Inquiries: 
Deanne Eagle 
Planet Communications 
917-837-5866
deanne@planetcommunications.nyc